Indevus Pharmaceuticals

Indevus announces positive phase III data for Sanctura XR for overactive bladder

Published in Law and Health Weekly, July 15th, 2006

Indevus Pharmaceuticals, Inc., (IDEV) announced data from the first of two phase III clinical trials with Sanctura XR for overactive bladder (OAB).

Sanctura XR is the once-daily formulation of Sanctura, which is currently marketed for overactive bladder. The data from the recently completed trial showed that Sanctura XR met its primary endpoints, reduction in frequency of urination (toilet voids) and reduction in number of urge incontinent episodes. The trial also achieved all of its key secondary endpoints, including an increase in volume voided and a reduction in the severity of urgency, a defining symptom of OAB. In addition, the drug was extremely well-tolerated and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2006-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry